Skip to main content
. 2021 Jan 20;9(1):e001765. doi: 10.1136/bmjdrc-2020-001765

Figure 1.

Figure 1

Flow chart of patient enrollment and exclusions for the SGLT2i ‘clean’ versus DPP-4i ‘clean’ cohorts, as well as for the SGLT2i ‘add-on’ versus SGLT2i ‘switch’ cohorts. The flow chart also indicates the change in the number of cases due to propensity score matching. DPP-4i, dipeptidyl-peptidase-4 inhibitor; PCOS, polycystic ovary syndrome; SGLT2i, sodium-glucose cotransporter-2 inhibitor.